Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,108.40
(
-0.41%
)
US TECH 100
26,203.20
(
0.00%
)
Dow Jones
49,310.32
(
-0.36%
)
Brent Oil
101.26
(
0.05%
)
Bitcoin
78,445.09
(
0.21%
)
News Focus
News Focus
Post# of 257441
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122884
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 96710

Monday, 04/11/2011 4:56:58 AM

Monday, April 11, 2011 4:56:58 AM

Post# of 257441
Tasigna-vs-Gleevec phase-3 GIST study halted for futility:

http://www.novartis.com/newsroom/media-releases/en/2011/1504991.shtml

The study was halted because Tasigna had little chance to show statsig superiority to Gleevec in PFS, the primary endpoint. The GIST failure is somewhat surprising insofar as Tasigna bested Gleevec with ease in first-line CML (#msg-50898190).

The description of the GIST study is at: http://clinicaltrials.gov/ct2/show/NCT00785785 .

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today